However, it remains unknown whether PARPi treatment activate STAT3 in ovarian cancer patient tumors to promote therapy resistance, and whether PARPi impact STAT3 activity in tumor-associated immune cells to suppress their ability to mount antitumor immune responses. The gene discussed is STAT3; the disease is neoplasm.